This educational activity is based on case presentations and subsequent small group discussions of patients with hematologic malignancies that are being evaluated, treated and followed in the Department of Hematology and Oncology, and that have diagnostic or follow-up material evaluated in the Division of Hematopathology. The goal of this multimodality approach is to ensure that the best patient care is being delivered by both Hematologists/Oncologists and Pathologists.
Key Words: CME, MCW, Pathology, Clinical Pathology, Molecular Pathology, Hematologic Neoplasms, Hematologic Tests, Hematologic Diseases, Morphological and Microscopic Findings, Diagnostic Techniques and Procedures, Clinical Laboratory Techniques, Hemic and Immune Systems, Differential Diagnosis, Pathological Processes, Neoplastic Cell Transformation
Learning objectives are identified for Hematologists/Oncologists and Hematopathologists.
Participants who engage in this educational intervention will be able to:
- Identify appropriate ordering of expensive, ancillary diagnostic testing
- Describe the salient morphologic, immunophenotypic, cytogenetic and molecular features of common hematologic malignancies
- Discuss emergent therapeutic options and availability of clinical trials, and how they apply to patients diagnosed in our service
- Utilize and constantly update themselves with the clinical practices of the Department of Hematology and Oncology, in order to continue to improve outcomes and provide optimal patient care
In accordance with the ACCME® Standards for Commercial Support Six, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
- Alexandra Harrington, MD, MT(ASCP)CM
- Steven H. Kroft, MD
- Shannon M. Majewski, CMP, CMM, HMCC, VEMM
In accordance with the ACCME® Standards for Commercial Support Six, all in control of content must disclose any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
|Ehab Atallah, MD||Novartis||Consultant|
|Ehab Atallah, MD||Takeda||Researcher; Consultant|
|Ehab Atallah, MD||Abbvie||Researcher; Consultant|
|Ehab Atallah, MD||Adaptive Biotechnologies||Consultant|
|Ehab Atallah, MD||Foundation One||Advisory Board|
|Ehab Atallah, MD||Celgene||Consultant|
|Ehab Atallah, MD||Genentech||Consultant|
|Laura Michaelis, MD||Jazz Pharmaceuticals||Clinical Trial|
|Laura Michaelis, MD||Society of Hematologic Oncology||Educational Board Member & Speaker|
|Laura Michaelis, MD||Wintrobe's Publishing||Editor, Malignant Hematology|
|Laura Michaelis, MD||ASH||Editor in Chief of Hematologist; Speaker; Author, National Publications|
|Laura Michaelis, MD||ABIM||Committee Member|
|Laura Michaelis, MD||Curio Science||Consulting, Advisory Board|
|Laura Michaelis, MD||Celgene Corp||Consulting, Advisory Board|
|Laura Michaelis, MD||Incyte Corporation||Report, Deposition, Civil Litigation Testimony|
AMA Credit Designation Statement:
Hours of Participation for Allied Health Professionals
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit and ABPath MOC credit.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.